Another genome-wide RNA interference screen implicates NF1 loss in conferring resistance to type 1 RAFi in BRAF V600E-mutant cancers, while cancer cells harboring BRAF V600E and NF1 loss retain sensitivity to type 2 RAFi and ERKi, further suggesting the activity of vertical inhibition of ERK signaling with combination regimen consisting of type 2 RAFi in NF1 loss tumors (Whittaker et al. 2013). The gene discussed is BRAF; the disease is cancer.